Chen Ru, Lai Lisa A, Brentnall Teresa A, Pan Sheng
Ru Chen, Lisa A Lai, Teresa A Brentnall, Sheng Pan, Department of Medicine, University of Washington, Seattle, WA 98195, United States.
World J Gastroenterol. 2016 Sep 21;22(35):7882-91. doi: 10.3748/wjg.v22.i35.7882.
Patients with extensive ulcerative colitis (UC) of more than eight years duration have an increased risk of colorectal cancer. Molecular biomarkers for dysplasia and cancer could have a great clinical value in managing cancer risk in these UC patients. Using a wide range of molecular techniques - including cutting-edge OMICS technologies - recent studies have identified clinically relevant biomarker candidates from a variety of biosamples, including colonic biopsies, blood, stool, and urine. While the challenge remains to validate these candidate biomarkers in multi-center studies and with larger patient cohorts, it is certain that accurate biomarkers of colitis-associated neoplasia would improve clinical management of neoplastic risk in UC patients. This review highlights the ongoing avenues of research in biomarker development for colitis-associated colorectal cancer.
病程超过八年的广泛性溃疡性结肠炎（UC）患者患结直肠癌的风险增加。发育异常和癌症的分子生物标志物在管理这些UC患者的癌症风险方面可能具有重大临床价值。利用广泛的分子技术——包括前沿的组学技术——最近的研究已经从各种生物样本中鉴定出具有临床相关性的候选生物标志物，这些生物样本包括结肠活检组织、血液、粪便和尿液。尽管在多中心研究和更大的患者队列中验证这些候选生物标志物仍然是一项挑战，但可以肯定的是，结肠炎相关肿瘤形成的准确生物标志物将改善UC患者肿瘤风险的临床管理。本综述重点介绍了结肠炎相关结直肠癌生物标志物开发方面正在进行的研究途径。
